<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004036</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066347</org_study_id>
    <secondary_id>CCF-IRB-1907</secondary_id>
    <secondary_id>IMMUNEX-001.G9701</secondary_id>
    <secondary_id>NCI-V98-1424</secondary_id>
    <nct_id>NCT00004036</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they
      stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from
      the side effects of chemotherapy.

      PURPOSE: Phase I trial to study the effectiveness of amifostine plus combination chemotherapy
      in treating patients with advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the effects of priming on the granulocyte and thrombocyte nadirs
      produced by high dose cyclophosphamide and carboplatin in patients with advanced
      malignancies. II. Determine the effects of amifostine on the granulocyte and thrombocyte
      nadirs produced by this same regimen when administered with sargramostim primed progenitor
      cells. III. Determine the maximum tolerated dose of cyclophosphamide and carboplatin that can
      be administered with sargramostim primed progenitor cells.

      OUTLINE: This is a dose escalation study. Patients receive intravenous amifostine over 10
      minutes on day 0, followed by intravenous cyclophosphamide and carboplatin consecutively over
      5-15 minutes. Sargramostim is administered subcutaneously on days -7 to -2 and again
      beginning on day 1 until absolute neutrophil count is appropriate. Course is repeated every
      28 days until disease progression or unacceptable toxic effects are observed. Nonresponding
      patients discontinue treatment after 2 courses. Patients are treated for a maximum of 6
      courses. Groups of 3-6 patients receive escalating doses of cyclophosphamide and carboplatin
      until the maximum tolerated dose (MTD) is determined. If dose limiting toxicity (DLT) occurs
      in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose
      is declared the MTD.

      PROJECTED ACCRUAL: Approximately 24-30 patients will be accrued for this study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 1997</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous Condition</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven advanced malignancies that are sensitive to
        cyclophosphamide/carboplatin therapy OR refractory to standard therapy, including, but not
        limited to: Ovarian epithelial cancer Colorectal cancer Breast cancer Sarcoma Non-small
        cell lung cancer Malignant melanoma Upper gastrointestinal cancers Small cell lung cancer

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 SWOG 0-2 Life
        expectancy: At least 3 months Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 8.5 g/dL
        Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR
        Creatinine clearance at least 60 mL/min OR Iothalamate clearance at least 60 mL/min
        Cardiovascular: No significant coronary artery disease (angina of New York Heart
        Association class 3 or greater) Other: Not pregnant or nursing Negative pregnancy test
        Fertile patients must use effective contraception No psychosis

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: At
        least 3 weeks since prior chemotherapy and recovered No more than 1 prior chemotherapy
        regimen for advanced or recurrent malignancies (not including adjuvant chemotherapy) No
        prior nitrosoureas or intravenous mitomycin No concurrent cytotoxic chemotherapy Endocrine
        therapy: At least 1 week since prior hormone therapy and recovered Concurrent
        corticosteroid therapy allowed Radiotherapy: At least 3 weeks since prior radiotherapy and
        recovered Radiotherapy allowed to no more than 1 site in the thoracic or lumbar spine or
        pelvis Concurrent radiotherapy to a symptomatic lesion allowed after the first course of
        study treatment Surgery: At least 3 weeks since prior surgery and recovered (excluding
        recent biopsy or placement of an intravenous access device)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Thomas Budd, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

